Debate on long-acting β agonists for asthma: they think it's all over

Brian Lipworth (Lead / Corresponding author), Sunny Jabbal

Research output: Contribution to journalLetter

1 Citation (Scopus)
114 Downloads (Pure)

Abstract

At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?
Original languageEnglish
Pages (from-to)e14-e15
Number of pages2
JournalThe Lancet Respiratory Medicine
Volume5
Issue number3
Early online date28 Feb 2017
DOIs
Publication statusPublished - Mar 2017

Fingerprint

Asthma
Adrenal Cortex Hormones
Nebulizers and Vaporizers
United States Food and Drug Administration
Guidelines

Keywords

  • Letter

Cite this

@article{01481158349341b3bcd7824c620c413a,
title = "Debate on long-acting β agonists for asthma: they think it's all over",
abstract = "At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?",
keywords = "Letter",
author = "Brian Lipworth and Sunny Jabbal",
note = "BL reports grants and personal fees from Teva, Boehringer Ingelheim, Meda, and Chiesi Pharma; personal fees from Dr Reddy's, Sandoz, and Lupin; grants from AstraZeneca, Janssen, Roche, and Sanofi; and other support from Napp, outside of the submitted work. SJ reports personal fees and non-financial support from Chiesi Pharma, non-financial support from Pfizer and Napp, and other support from Napp, outside of the submitted work.",
year = "2017",
month = "3",
doi = "10.1016/S2213-2600(17)30053-X",
language = "English",
volume = "5",
pages = "e14--e15",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Debate on long-acting β agonists for asthma

T2 - they think it's all over

AU - Lipworth, Brian

AU - Jabbal, Sunny

N1 - BL reports grants and personal fees from Teva, Boehringer Ingelheim, Meda, and Chiesi Pharma; personal fees from Dr Reddy's, Sandoz, and Lupin; grants from AstraZeneca, Janssen, Roche, and Sanofi; and other support from Napp, outside of the submitted work. SJ reports personal fees and non-financial support from Chiesi Pharma, non-financial support from Pfizer and Napp, and other support from Napp, outside of the submitted work.

PY - 2017/3

Y1 - 2017/3

N2 - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?

AB - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?

KW - Letter

U2 - 10.1016/S2213-2600(17)30053-X

DO - 10.1016/S2213-2600(17)30053-X

M3 - Letter

C2 - 28266330

VL - 5

SP - e14-e15

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 3

ER -